Assessment of disease progression in motor neuron disease.
Motor neuron disease (MND) is characterised by progressive deterioration of the corticospinal tract, brainstem, and anterior horn cells of the spinal cord. There is no pathognomonic test for the diagnosis of MND, and physicians rely on clinical criteria-upper and lower motor neuron signs-for diagnosis. The presentations, clinical phenotypes, and outcomes of MND are diverse and have not been combined into a marker of disease progression. No single algorithm combines the findings of functional assessments and rating scales, such as those that assess quality of life, with biological markers of disease activity and findings from imaging and neurophysiological assessments. Here, we critically appraise developments in each of these areas and discuss the potential of such measures to be included in the future assessment of disease progression in patients with MND.
Winhammar
Jennica M C
JM
Department of Neurology and Multidisciplinary Motor Neurone Disease Clinic, Royal North Shore Hospital, NSW, Australia.
Rowe
Dominic B
DB
Henderson
Robert D
RD
Kiernan
Matthew C
MC
D000465:Algorithms; D015415:Biomarkers; D001921:Brain / Q000473:pathology; D018450:Disease Progression; D006801:Humans; D016472:Motor Neuron Disease / Q000175:diagnosis / Q000503:physiopathology
D015415:Biomarkers